- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BEAM
Recent news which mentions BEAM
Is Beam Therapeutics a Good Stock to Buy Now?
January 16, 2022
From Motley Fool
Why Editas Medicine Stock Is Tumbling This Week
January 13, 2022
From Motley Fool
Pfizer, Beam Ink Multi-Target Research Collaboration For In Vivo Base Editing Programs
January 10, 2022
From Benzinga
My 3 Top Biotech Stock Picks for 2022
January 09, 2022
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
January 05, 2022
From Benzinga
Top 5 Moonshots for 2022 Countdown: My No. 5 Pick
December 22, 2021
From InvestorPlace
8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022
December 07, 2021
From Motley Fool
Got $1,000? Check Out These 3 Top Biotech Stocks
December 03, 2021
From Motley Fool
Direxion Launches New Nanotechnology ETF, TYNE
November 23, 2021
From ETF Trends
Being First Is Not Enough For Crispr Therapeutics
November 15, 2021
From InvestorPlace
In Conversation: CMC Markets and ARK Investment Management on the Future of Genomic Testing
November 12, 2021
Tickers
BEAM
From Benzinga
Cathie Wood's Buying Beam Therapeutics -- Should You?
November 09, 2021
From Motley Fool
Looking Into Beam Therapeutics's Return On Capital Employed
November 08, 2021
Tickers
BEAM
From Benzinga
3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too
October 26, 2021
From Motley Fool
If I Could Only Own 1 Healthcare Stock, This Is What It Would Be
October 21, 2021
From Motley Fool
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
October 19, 2021
From Benzinga
2 Gene-Editing Stocks to Have on Your Radar Right Now
October 17, 2021
From Motley Fool
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
October 15, 2021
From Motley Fool
Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought
October 12, 2021
From Motley Fool
Got $500? 3 Game-Changing Stocks to Buy Right Now
October 04, 2021
From Motley Fool
Step Aside, Genomic Revolution. Welcome, the Proteomic Revolution!
October 03, 2021
Tickers
BEAM
From InvestorPlace
3 Most Overvalued Biotech Stocks on the Market Right Now
October 01, 2021
From Motley Fool
Breaking Down CRISPR Technology
September 28, 2021
From Motley Fool
Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection
September 27, 2021
Tickers
BEAM
From Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
September 23, 2021
From Benzinga
Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies
September 23, 2021
Tickers
BEAM
From Benzinga
Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another
September 23, 2021
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.